MARC details
| 000 -LEADER |
|---|
| fixed length control field |
01921nam a22002417a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
MED20160011 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20240720153040.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
180906b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
FEU-NRMF MEDICAL LIBRARY |
| 041 ## - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
English |
| 050 ## - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
MED20160011 |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Sanchez, Jennelyn A., MD. |
| Relator term |
author |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
A Different kind of mm : |
| Remainder of title |
a rare case of mm revealed / |
| Statement of responsibility, etc. |
Jennelyn A. Sanchez. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc. |
Fairview, Quezon City |
| Name of publisher, distributor, etc. |
Department of Internal Medicine, FEU-NRMF, |
| Date of publication, distribution, etc. |
2016 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Other physical details |
photos (black and white); |
| Dimensions |
(in folder) |
| 336 ## - CONTENT TYPE |
|---|
| Source |
text |
| Content type term |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Source |
unmediated |
| Media type term |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Source |
volume |
| Carrier type term |
rdacarrier |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
ABSTRACT: Multiple myeloma is a malignant disease characterized by plasmacytosis, paraprotien production, bone lesions, hypercalcemia, susceptibility to infections, and renal impairment. The underlying pathophysiologic phenomena of the clinical features include suppression of humoral-and cell-mediated immunity, elevation of IL-6, abnormalities of the bone marrow microenvironment, and increased osteoclastic activity. Overwhelming predictors of prognosis include albumin, β2-microglobulin, and chomosomal karyotype. With modern, intensive therapy including autologous hematopoietic stem cell transplantation, the median survival is approximately 5 yr. The disease is incurable and eventually relapse; requiring salvage therapy. The development of newer agents such as thalidomide, bortezomid, and lenalidomide-drugs that interfere with several of the complex pathophysiologic steps-has improved the outlook of relapsed disease significantly. Current studies are directed at exploring the use of these novel agents earlier in the course of therapy, development of newer targeted therapies, and the use of gene expression profiling to individualize therapy. |
| 521 ## - TARGET AUDIENCE NOTE |
|---|
| Target audience note |
Research - Department of Medicine |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
Research |
